Study of PAN-90806 Eye Drops, Suspension for Neovascular AMD

Inclusion Criteria: * Diagnosis in the study eye of active, pathologic, newly diagnosed and previously untreated, subfoveal choroidal neovascular (CNV) lesions secondary to neovascular AMD * Aged 50 years or older * Demonstrate the ability, or have a family member who is willing and able, to instill topical ocular drops in the study eye Exclusion Criteria: * Prior ocular or systemic treatment or surgery for neovascular AMD in the study eye * Prior use within the last 3 months or a high possibility of requiring treatment with anti-VEGF therapy in the fellow eye during the study * Significant retinal serous pigment epithelial detachment (PED), atrophy, or fibrosis/scar involving the fovea * History of or current clinical evidence in the study eye of aphakia, diabetic macular edema, any ocular inflammation or infections, pathological myopia, retinal detachment, advanced glaucoma, and/or significant media opacity, including cataract * History or evidence of the following surgeries in the study eye: penetrating keratoplasty or vitrectomy; corneal transplant; corneal or intraocular surgery within 3 months of Screening * Uncontrolled hypertension despite use of antihypertensive medications * Participation in any investigational drug or device study, systemic or ocular, within past 3 months * Women who are pregnant or nursing * Women of child-bearing potential who are not using a highly effective form of birth control * Known serious allergies or hypersensitivity to the fluorescein dye used in angiography or to the components of the PAN-90806 formulation